In diagnostics, Johns Hopkins researchers reported clinical validation support for the first FDA-cleared rapid urine test aimed at invasive aspergillosis, designed to speed identification by detecting disease-associated signals in urine. On treatment evaluation, a systematic review and meta-analysis found no consistent mortality reduction from inhaled nitric oxide in preterm babies with respiratory failure, reinforcing the need for phenotype-driven therapy rather than broad deployment. In vaccine development, a phase 1 trial of an experimental whole-virus inactivated influenza vaccine reported good tolerability and broad antibody responses across multiple influenza subtypes, including route-dependent signals, supporting continued early-stage development.